Mouse anti Human Cytochrome P450 3A5

Product Specifications

Background

CYP3A genes encode monooxygenases, enzymes which catalyze drug metabolism and the synthesis of cholesterol, steroids and other lipids. CYP3A (cytochrome P450, family 3, subfamily A), the most abundant p450 enzyme in Human liver, is responsible for the metabolism of more than 50% of all clinical drugs. CYP3A members localize in organs that associate with drug disposition, including the liver, gastrointestinal tract and kidney. The CYP3A cluster consists of four genes: CYP3A43, CYP3A4, CYP3A7 and CYP3A5, and two pseudogenes: CYP3A5P1 and CYP3A5P2. The CYP3A cluster maps to gene locus 7q21.3-q22.1.

CAS Number

9007-83-4

Synonyms

CYP3A5, CYP450 3A5 (EC 1.14.14.1), Niphedipine oxidase, CYPIIIA5, P450-PCN3, HLp2

UniProt

P20815 (Human)

Host

Mouse

Species Reactivity

Human

Isotype

IgG1

Clone

F18 P3 B6

Conjugation

Unconjugated

Type

Monoclonal Antibody

Applications

WB, ELISA, IHC

Field of Research

Cell Cycle

Purification Method

Protein A/G Chromatography

Assay Principle

Antibody can be used for Western blotting (1-2 µg/mL) and immunohistochemistry on formalin-fixed, paraffin-embedded tissues (1-5 µg/mL). When used in conjunction with CYP3A7 (Cat. No. X2048M), can differentiate between the CYP3A family members, 3A5 and 3A7. Optimal concentration should be evaluated by serial dilutions.

Stability

See expiration date on vial

Concentration

See vial for Concentration

Form

Provided as solution in phosphate buffered saline with 0,08% sodium azide

Precautions

This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving Humans or animals.

References & Citations

1. Kumarakasingham, M., et al. (2005). Cytochrome p450 profile of colorectal cancer: Identification of markers of prognosis. Clin. Cancer Res. 11(10);3758-3765. 2. McCune, J.S., et al (2005). Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethlation. Drug Metab. Dispos. 33(7);1074-1081. 3. Kim, K.A., et al. (2007). Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J. Cin. Pharmacol. 47(1);87-93